Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease

Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a mult...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2018-06, Vol.265 (6), p.1279-1287
Main Authors: Catalan, Maria Jose, Molina-Arjona, Jose Antonio, Mir, Pablo, Cubo, Esther, Arbelo, Jose Matias, Martinez-Martin, Pablo
Format: Article
Language:English
Subjects:
Caregivers
Impulsive behavior
Intestine
Levodopa
Medicine
Medicine & Public Health
Mental disorders
Movement disorders
Neurodegenerative diseases
Neurology
Neuroradiology
Neurosciences
Obsessive compulsive disorder
Original Communication
Ostomy
Parkinson's disease
Patients
Quality of life
Sleep
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3
cites cdi_FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3
container_end_page 1287
container_issue 6
container_start_page 1279
container_title Journal of neurology
container_volume 265
creator Catalan, Maria Jose
Molina-Arjona, Jose Antonio
Mir, Pablo
Cubo, Esther
Arbelo, Jose Matias
Martinez-Martin, Pablo
description Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a multicenter, observational, and prospective (6 months follow-up) study that included consecutive PD patients assigned to LCIG through routine medical practice. Patients completed visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy procedure. The following outcomes were evaluated: presence and severity of ICDs and other neuropsychiatric disorders, sleep disturbances, patients’ quality of life, and caregivers’ burden. Sixty-two patients were included at baseline: mean age 72.2 years (SD ± 7.0), 42% women. Median duration of PD symptoms was 13.5 years (IQR 5.5–21.5) and median time with motor fluctuations was 5.0 years (IQR 1.0–9.0). Treatment with LCIG infusion was associated with progressive and significant improvements in ICDs symptoms over the study period (64.4% reduction in the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease—Rating Scale score). Psychotic and other neuropsychiatric symptoms were also significantly reduced, and patients’ sleep quality and psychosocial function improved. Caregivers’ burden remained unchanged. There was a significant improvement in the daily “Off” time [7.4 h (SD ± 4.0) vs 1.5 h (SD ± 1.8); p  
doi_str_mv 10.1007/s00415-018-8803-1
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2015832536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2015832536</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3</originalsourceid><addsrcrecordid>eNp1kbFuFDEURS0EIpvAB9AgSzQ0A8_2eMcuUQQkUiRSQG15x2-Cw4y92J6N6FLSU_F7-RI87BIkJNzY0jv3Xj9dQp4xeMUAutcZoGWyAaYapUA07AFZsVbwhrVSPyQrEC00Usj2iBznfA0Aqg4ekyOupey00ivy_XzaprjDCUOhcaB-2s5jRtrHUFIcqfM5JocpU5tz7L0t6OiNL5_piLvo4tbe3f7obdr45U19KJiLD3akVzjSktCW39Y-UOt2NvRVfmnTFx9yDHe3P_OSgDbjE_JosDX56eE-IZ_evf14etZcfHh_fvrmoumFVqVBMaihXbfWatDgOrEB4ZzWjg8gGdc4KCe4Fpwj34BSTNsO1s7ZQYCrR5yQl3vfuvbXuX7WTD73OI42YJyz4cCkElyKdUVf_INexznV3Q5Up1S3UGxP9SnmnHAw2-Qnm74ZBmapyexrMrUms9RkWNU8PzjPmwndveJPLxXgeyDXUbjC9Df6_66_AFsHokM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2015878876</pqid></control><display><type>article</type><title>Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease</title><source>Springer Link</source><creator>Catalan, Maria Jose ; Molina-Arjona, Jose Antonio ; Mir, Pablo ; Cubo, Esther ; Arbelo, Jose Matias ; Martinez-Martin, Pablo</creator><creatorcontrib>Catalan, Maria Jose ; Molina-Arjona, Jose Antonio ; Mir, Pablo ; Cubo, Esther ; Arbelo, Jose Matias ; Martinez-Martin, Pablo ; EDIS Study Group ; On behalf of the EDIS Study Group</creatorcontrib><description>Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a multicenter, observational, and prospective (6 months follow-up) study that included consecutive PD patients assigned to LCIG through routine medical practice. Patients completed visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy procedure. The following outcomes were evaluated: presence and severity of ICDs and other neuropsychiatric disorders, sleep disturbances, patients’ quality of life, and caregivers’ burden. Sixty-two patients were included at baseline: mean age 72.2 years (SD ± 7.0), 42% women. Median duration of PD symptoms was 13.5 years (IQR 5.5–21.5) and median time with motor fluctuations was 5.0 years (IQR 1.0–9.0). Treatment with LCIG infusion was associated with progressive and significant improvements in ICDs symptoms over the study period (64.4% reduction in the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease—Rating Scale score). Psychotic and other neuropsychiatric symptoms were also significantly reduced, and patients’ sleep quality and psychosocial function improved. Caregivers’ burden remained unchanged. There was a significant improvement in the daily “Off” time [7.4 h (SD ± 4.0) vs 1.5 h (SD ± 1.8); p  &lt; 0.0001] at the end of follow-up, whereas duration of dyskinesias was not affected. ICDs significantly improved after 6-month LCIG treatment in a group of PD patients with mild-to-moderate neuropsychiatric disturbances.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-018-8803-1</identifier><identifier>PMID: 29557989</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Caregivers ; Impulsive behavior ; Intestine ; Levodopa ; Medicine ; Medicine &amp; Public Health ; Mental disorders ; Movement disorders ; Neurodegenerative diseases ; Neurology ; Neuroradiology ; Neurosciences ; Obsessive compulsive disorder ; Original Communication ; Ostomy ; Parkinson's disease ; Patients ; Quality of life ; Sleep</subject><ispartof>Journal of neurology, 2018-06, Vol.265 (6), p.1279-1287</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Journal of Neurology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3</citedby><cites>FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29557989$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catalan, Maria Jose</creatorcontrib><creatorcontrib>Molina-Arjona, Jose Antonio</creatorcontrib><creatorcontrib>Mir, Pablo</creatorcontrib><creatorcontrib>Cubo, Esther</creatorcontrib><creatorcontrib>Arbelo, Jose Matias</creatorcontrib><creatorcontrib>Martinez-Martin, Pablo</creatorcontrib><creatorcontrib>EDIS Study Group</creatorcontrib><creatorcontrib>On behalf of the EDIS Study Group</creatorcontrib><title>Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a multicenter, observational, and prospective (6 months follow-up) study that included consecutive PD patients assigned to LCIG through routine medical practice. Patients completed visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy procedure. The following outcomes were evaluated: presence and severity of ICDs and other neuropsychiatric disorders, sleep disturbances, patients’ quality of life, and caregivers’ burden. Sixty-two patients were included at baseline: mean age 72.2 years (SD ± 7.0), 42% women. Median duration of PD symptoms was 13.5 years (IQR 5.5–21.5) and median time with motor fluctuations was 5.0 years (IQR 1.0–9.0). Treatment with LCIG infusion was associated with progressive and significant improvements in ICDs symptoms over the study period (64.4% reduction in the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease—Rating Scale score). Psychotic and other neuropsychiatric symptoms were also significantly reduced, and patients’ sleep quality and psychosocial function improved. Caregivers’ burden remained unchanged. There was a significant improvement in the daily “Off” time [7.4 h (SD ± 4.0) vs 1.5 h (SD ± 1.8); p  &lt; 0.0001] at the end of follow-up, whereas duration of dyskinesias was not affected. ICDs significantly improved after 6-month LCIG treatment in a group of PD patients with mild-to-moderate neuropsychiatric disturbances.</description><subject>Caregivers</subject><subject>Impulsive behavior</subject><subject>Intestine</subject><subject>Levodopa</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental disorders</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Obsessive compulsive disorder</subject><subject>Original Communication</subject><subject>Ostomy</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Sleep</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kbFuFDEURS0EIpvAB9AgSzQ0A8_2eMcuUQQkUiRSQG15x2-Cw4y92J6N6FLSU_F7-RI87BIkJNzY0jv3Xj9dQp4xeMUAutcZoGWyAaYapUA07AFZsVbwhrVSPyQrEC00Usj2iBznfA0Aqg4ekyOupey00ivy_XzaprjDCUOhcaB-2s5jRtrHUFIcqfM5JocpU5tz7L0t6OiNL5_piLvo4tbe3f7obdr45U19KJiLD3akVzjSktCW39Y-UOt2NvRVfmnTFx9yDHe3P_OSgDbjE_JosDX56eE-IZ_evf14etZcfHh_fvrmoumFVqVBMaihXbfWatDgOrEB4ZzWjg8gGdc4KCe4Fpwj34BSTNsO1s7ZQYCrR5yQl3vfuvbXuX7WTD73OI42YJyz4cCkElyKdUVf_INexznV3Q5Up1S3UGxP9SnmnHAw2-Qnm74ZBmapyexrMrUms9RkWNU8PzjPmwndveJPLxXgeyDXUbjC9Df6_66_AFsHokM</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Catalan, Maria Jose</creator><creator>Molina-Arjona, Jose Antonio</creator><creator>Mir, Pablo</creator><creator>Cubo, Esther</creator><creator>Arbelo, Jose Matias</creator><creator>Martinez-Martin, Pablo</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180601</creationdate><title>Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease</title><author>Catalan, Maria Jose ; Molina-Arjona, Jose Antonio ; Mir, Pablo ; Cubo, Esther ; Arbelo, Jose Matias ; Martinez-Martin, Pablo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Caregivers</topic><topic>Impulsive behavior</topic><topic>Intestine</topic><topic>Levodopa</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental disorders</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Obsessive compulsive disorder</topic><topic>Original Communication</topic><topic>Ostomy</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Sleep</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catalan, Maria Jose</creatorcontrib><creatorcontrib>Molina-Arjona, Jose Antonio</creatorcontrib><creatorcontrib>Mir, Pablo</creatorcontrib><creatorcontrib>Cubo, Esther</creatorcontrib><creatorcontrib>Arbelo, Jose Matias</creatorcontrib><creatorcontrib>Martinez-Martin, Pablo</creatorcontrib><creatorcontrib>EDIS Study Group</creatorcontrib><creatorcontrib>On behalf of the EDIS Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catalan, Maria Jose</au><au>Molina-Arjona, Jose Antonio</au><au>Mir, Pablo</au><au>Cubo, Esther</au><au>Arbelo, Jose Matias</au><au>Martinez-Martin, Pablo</au><aucorp>EDIS Study Group</aucorp><aucorp>On behalf of the EDIS Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>265</volume><issue>6</issue><spage>1279</spage><epage>1287</epage><pages>1279-1287</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a multicenter, observational, and prospective (6 months follow-up) study that included consecutive PD patients assigned to LCIG through routine medical practice. Patients completed visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy procedure. The following outcomes were evaluated: presence and severity of ICDs and other neuropsychiatric disorders, sleep disturbances, patients’ quality of life, and caregivers’ burden. Sixty-two patients were included at baseline: mean age 72.2 years (SD ± 7.0), 42% women. Median duration of PD symptoms was 13.5 years (IQR 5.5–21.5) and median time with motor fluctuations was 5.0 years (IQR 1.0–9.0). Treatment with LCIG infusion was associated with progressive and significant improvements in ICDs symptoms over the study period (64.4% reduction in the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease—Rating Scale score). Psychotic and other neuropsychiatric symptoms were also significantly reduced, and patients’ sleep quality and psychosocial function improved. Caregivers’ burden remained unchanged. There was a significant improvement in the daily “Off” time [7.4 h (SD ± 4.0) vs 1.5 h (SD ± 1.8); p  &lt; 0.0001] at the end of follow-up, whereas duration of dyskinesias was not affected. ICDs significantly improved after 6-month LCIG treatment in a group of PD patients with mild-to-moderate neuropsychiatric disturbances.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29557989</pmid><doi>10.1007/s00415-018-8803-1</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-5354
ispartof Journal of neurology, 2018-06, Vol.265 (6), p.1279-1287
issn 0340-5354
1432-1459
language eng
recordid cdi_proquest_miscellaneous_2015832536
source Springer Link
subjects Caregivers
Impulsive behavior
Intestine
Levodopa
Medicine
Medicine & Public Health
Mental disorders
Movement disorders
Neurodegenerative diseases
Neurology
Neuroradiology
Neurosciences
Obsessive compulsive disorder
Original Communication
Ostomy
Parkinson's disease
Patients
Quality of life
Sleep
title Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20impulse%20control%20disorders%20associated%20with%20levodopa%E2%80%93carbidopa%20intestinal%20gel%20treatment%20in%20advanced%20Parkinson%E2%80%99s%20disease&rft.jtitle=Journal%20of%20neurology&rft.au=Catalan,%20Maria%20Jose&rft.aucorp=EDIS%20Study%20Group&rft.date=2018-06-01&rft.volume=265&rft.issue=6&rft.spage=1279&rft.epage=1287&rft.pages=1279-1287&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-018-8803-1&rft_dat=%3Cproquest_cross%3E2015832536%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c398t-e3f8f464aa9090d73b03dd99d2f05129ef8d329322e2b08819a706ddaf30dddd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2015878876&rft_id=info:pmid/29557989&rfr_iscdi=true